Cara Therapeutics Inc (NASDAQ:CARA) posted its quarterly earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.31. Cara Therapeutics Inc (NASDAQ:CARA) stock performance was 3.44% in last session and finished the day at $19.25. Traded volume was 234.6K shares in the last session and the average volume of the stock remained 298.33K shares. Cara Therapeutics Inc (NASDAQ:CARA) insider ownership is 7.20%.

Prothena Corporation PLC (NASDAQ:PRTA) touched a 52-week high after the company announced that interim data from a phase I study on its pipeline candidate, NEOD001, will be presented at the XIV International Symposium on Amyloidosis (:ISA). The study is evaluating the safety, tolerability, pharmacokinetics and immunogenicity of the candidate in patients suffering from immunoglobulin light chain (AL) amyloidosis and persistent organ dysfunction. The company has plans to initiate a phase II/III study on the candidate in the fourth quarter of 2014. Prothena Corporation PLC (NASDAQ:PRTA) dropped -3.37 percent to $37.02 Tuesday on volume of 263.7K shares. The intra-day range of the stock was $36.14 to $39.55. Prothena Corporation PLC (NASDAQ:PRTA) has a market capitalization of $824.48million.

CorMedix Inc. (NYSEMKT:CRMD) hosted a conference call at 9:00 AM ET on April 1, 2014, and discussed Q4 13 earnings results. CorMedix Inc. (NYSEMKT:CRMD)’s stock on Apr 01, 2014 reported a decrease of -5.18% to the closing price of $2.38. Its fifty two weeks range is $0.48 -$3.20. The total market capitalization recorded $52.11million. The overall volume in the last trading session was 305,417.00million shares. In its share capital, CRMD has 21.88million outstanding shares.

Stemline Therapeutics, Inc. (NASDAQ:STML) announced that data demonstrating SL-501 inhibits the growth of tyrosine kinase inhibitor (TKI) resistant chronic myeloid leukemia (CML) cells in preclinical models was selected for poster presentation at the Annual Meeting of the American Association for Cancer Research (AACR) Conference, being held April 5-9, 2014 in San Diego, CA. SL-501 is a highly potent targeted therapy directed to the interleukin-3 receptor (IL-3R). SL-501 is a next generation variant of SL-401; SL-401 is currently being advanced in clinical trials of multiple hematologic cancers. On Tuesday, shares of Stemline Therapeutics Inc (NASDAQ:STML) dropped -2.90% to close the day at $19.77. Company monthly performance is recorded as -24.54%. Stemline Therapeutics Inc (NASDAQ:STML) quarterly revenue growth is -1.20%.